• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ligand Pharm (NQ: LGND )

    111.13 +0.91 (+0.83%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ligand Pharm

    < Previous 1 2 3 4 5 6 Next >
    Where Ligand Pharmaceuticals Stands With Analysts
    Via Benzinga
    Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Analyst Expectations for Ligand Pharmaceuticals's Future
    Via Benzinga
    Recap: Ligand Pharmaceuticals Q1 Earnings
    Via Benzinga
    Ligand Pharmaceuticals Earnings Preview
    Via Benzinga
    Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
    Via Benzinga
    Ligand Reports Second Quarter 2023 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand To Report Second Quarter 2023 Financial Results On August 8
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Why Are Novan Shares Nosediving Today?
    Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to  
    Via Benzinga
    Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
    From Novan, Inc.
    Via GlobeNewswire
    3 Stocks That Smart Investors Should Be Flocking to Now
    Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. 
    Via InvestorPlace
    Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
    Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
    Via Benzinga
    Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Reports First Quarter 2023 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
    Via Benzinga
    Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Earnings Scheduled For February 22, 2023
    Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
    Via Benzinga
    Ligand to Report Fourth Quarter Financial Results on February 22
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
    The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
    Via Benzinga
    Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Tesla To $175? Here Are 10 Other Price Target Changes For Friday
    Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
    Via Benzinga
    Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
    Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13. 
    Via Benzinga
    Ligand Pharma Issues Mixed Guidance For FY23
    At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its... 
    Via Benzinga
    Ligand Provides Highlights from its Investor and Analyst Day Event
    From Ligand Pharmaceuticals
    Via Business Wire
    Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.